¹⁸F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17514

Wonseok Whi, Hyunjong Lee, Jung Yong Hong, Wonseok Kang, Young Seok Cho, Seung Hwan Moon, Joon Young Choi, Kyung-Han Lee, Seung Hyup Hyun

{"title":"18F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.","authors":"Wonseok Whi, Hyunjong Lee, Jung Yong Hong, Wonseok Kang, Young Seok Cho, Seung Hwan Moon, Joon Young Choi, Kyung-Han Lee, Seung Hyup Hyun","doi":"10.21873/anticanres.17514","DOIUrl":null,"url":null,"abstract":"Background/aim: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and treatment outcomes for advanced disease remain suboptimal. Immunotherapy, particularly atezolizumab plus bevacizumab, has shown promise in improving survival. This study aimed to evaluate the prognostic value of 18F-fluorocholine positron emission tomography/computed tomography (FCH PET/CT) in patients with unresectable HCC undergoing this combination therapy.Patients and methods: This prospective study included 29 patients with unresectable HCC treated with atezolizumab plus bevacizumab. All participants underwent FCH PET/CT prior to treatment. The tumor-to-liver ratio (TLR) of FCH uptake was calculated and analyzed as a potential prognostic biomarker. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis, and Cox proportional hazards models evaluated associations between TLR and clinical outcomes.Results: Patients with higher TLR values of FCH uptake (cutoff: 1.36) demonstrated significantly shorter PFS compared to those with lower TLR values (hazard ratio=4.29, p=0.032). Other clinical variables, including age, sex, tumor size, and viral hepatitis status, were not significantly associated with PFS.Conclusion: TLR of FCH uptake is a valuable non-invasive biomarker for predicting PFS in unresectable HCC patients treated with immunotherapy.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1273-1280"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17514","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and treatment outcomes for advanced disease remain suboptimal. Immunotherapy, particularly atezolizumab plus bevacizumab, has shown promise in improving survival. This study aimed to evaluate the prognostic value of ¹⁸F-fluorocholine positron emission tomography/computed tomography (FCH PET/CT) in patients with unresectable HCC undergoing this combination therapy.

Patients and methods: This prospective study included 29 patients with unresectable HCC treated with atezolizumab plus bevacizumab. All participants underwent FCH PET/CT prior to treatment. The tumor-to-liver ratio (TLR) of FCH uptake was calculated and analyzed as a potential prognostic biomarker. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis, and Cox proportional hazards models evaluated associations between TLR and clinical outcomes.

Results: Patients with higher TLR values of FCH uptake (cutoff: 1.36) demonstrated significantly shorter PFS compared to those with lower TLR values (hazard ratio=4.29, p=0.032). Other clinical variables, including age, sex, tumor size, and viral hepatitis status, were not significantly associated with PFS.

Conclusion: TLR of FCH uptake is a valuable non-invasive biomarker for predicting PFS in unresectable HCC patients treated with immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.